• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

    2/14/23 10:06:00 AM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RXDX alert in real time by email
    SC 13G/A 1 p23-0498sc13ga.htm PROMETHEUS BIOSCIENCES, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     

    Prometheus Biosciences, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    74349U108

    (CUSIP Number)
     

    December 31, 2022

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 74349U108

    13G/APage 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    3,354,303 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    3,354,303 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,354,303 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.2%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. 74349U108

    13G/APage 3 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    3,354,303 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    3,354,303 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,354,303 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.2%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

     

     

    CUSIP No. 74349U108

    13G/APage 4 of 8 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Prometheus Biosciences, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 3050 Science Park Road, San Diego, California 92121.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Mr. Roderick Wong ("Mr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:

     

      RTW Investments is a Delaware limited partnership.  Mr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the "Shares").

     

     

     

    CUSIP No. 74349U108

    13G/APage 5 of 8 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      74349U108

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: ___________________________________________

       

     

    Item 4. OWNERSHIP:

     

       

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentages set forth herein are calculated based upon 46,393,636 Shares outstanding as of December 13, 2022, as reported in the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on December 9, 2022.

     

     

     

    CUSIP No. 74349U108

    13G/APage 6 of 8 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 74349U108

    13G/APage 7 of 8 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED:  February 14, 2023  
       
       
    RTW INVESTMENTS, LP  
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong  
    RODERICK WONG  
         

     

     

     

     

    CUSIP No. 74349U108

    13G/APage 8 of 8 Pages

    EXHIBIT 1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATE:  February 14, 2023  
       
       
    RTW INVESTMENTS, LP  
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong  
    RODERICK WONG  
         

     

    Get the next $RXDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXDX

    DatePrice TargetRatingAnalyst
    5/10/2023$160.00 → $200.00Buy → Hold
    Jefferies
    7/20/2022$51.00Buy
    Goldman
    6/10/2022$53.00Overweight
    Piper Sandler
    3/10/2022$50.00 → $52.00Outperform
    Credit Suisse
    3/10/2022$42.00 → $53.00Overweight
    Wells Fargo
    3/10/2022$47.00 → $55.00Outperform
    SVB Leerink
    2/11/2022$62.00Buy
    BTIG
    12/13/2021$46.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $RXDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cellino Appoints Chris Gibson to Board of Directors

      Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente

      10/24/24 8:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Completes Acquisition of Prometheus Biosciences, Inc.

      Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn's disease and other autoimmune conditions Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. ("Prometheus") (NASDAQ:RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. "The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is anoth

      6/16/23 4:04:00 PM ET
      $MRK
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

      SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. The transaction is expected to close in the th

      5/9/23 4:00:00 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cellino Appoints Chris Gibson to Board of Directors

      Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente

      10/24/24 8:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress

      - Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) - - Phase 1a trial results of PRA023 in normal healthy volunteers expected in fourth quarter 2021 - - Strong cash position of $304 million as of June 30, 2021 - SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bo

      8/11/21 4:01:00 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership

      Eleusis, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the appointment of four highly experienced business leaders to its board of directors. The new directors' deep expertise building high-growth, high-impact life science companies complements Eleusis's world-class leadership team. The appointees include: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chair of the board Robert Hershberg, M.D., Ph.D., former CBO and CSO of Celgene John Tucker, CEO of SC Pharmaceuticals Esther van den Boom, Managing Partner at van den Boom & Associates "We are delighted to welcome these four exceptional d

      7/12/21 8:00:00 AM ET
      $RXDX
      $PASG
      $PHAT
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $RXDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mckenna Mark C.

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:25 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Stenhouse Mark

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:32 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hendrix Martin

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:40 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prometheus Biosciences downgraded by Jefferies with a new price target

      Jefferies downgraded Prometheus Biosciences from Buy to Hold and set a new price target of $200.00 from $160.00 previously

      5/10/23 6:31:59 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Prometheus Biosciences with a new price target

      Goldman initiated coverage of Prometheus Biosciences with a rating of Buy and set a new price target of $51.00

      7/20/22 7:36:43 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Prometheus Biosciences with a new price target

      Piper Sandler initiated coverage of Prometheus Biosciences with a rating of Overweight and set a new price target of $53.00

      6/10/22 7:19:39 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Prometheus Biosciences Inc.

      15-12G - Prometheus Biosciences, Inc. (0001718852) (Filer)

      6/27/23 3:06:42 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Prometheus Biosciences Inc.

      25-NSE - Prometheus Biosciences, Inc. (0001718852) (Subject)

      6/16/23 9:13:06 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Prometheus Biosciences Inc.

      S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)

      6/16/23 9:12:56 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      3/8/23 5:02:07 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      2/14/23 4:27:18 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      2/14/23 3:01:42 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Financials

    Live finance-specific insights

    See more
    • Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb

      – ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all ranked secondary endpoints – – APOLLO-CD trial showed 26.0% endoscopic response and 49.1% clinical remission rates (p=0.002 and p<0.001, respectively, compared to prespecified historical placebo rates) – – PRA023 demonstrated favorable safety and tolerability results across both studies with no safety signal identified – – ARTEMIS-UC Cohort 1 interim analysis suggests a trend towards increased PRA023 response in CDx+ patients over all comers – – PRA023 showed a significant impact on multiple m

      12/7/22 7:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

      Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 indication to be presented in conference call scheduled today at 8:00 AM EST SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported positive topline results fro

      12/7/21 7:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care